Hot Flash Frequency and Blood Pressure: Data from the Study of Women's Health Across the Nation by Jackson, Elizabeth A. et al.
Original Articles
Hot Flash Frequency and Blood Pressure:
Data from the Study of Women’s Health Across the Nation
Elizabeth A. Jackson, MD, MPH,1 Samar R. El Khoudary, PhD, MPH,2 Sybil L. Crawford, PhD,3
Karen Matthews, PhD,2,4 Hadine Joffe, MD, MS,5 Claudia Chae, MD, MPH,6 and Rebecca C. Thurston, PhD2,4
Abstract
Background: Vasomotor symptoms (VMS) are highly prevalent among midlife women and have been asso-
ciated with subclinical cardiovascular disease (CVD). However, the association between VMS frequency and
risk factors such as hypertension (HTN) remains unclear.
Materials and Methods: We examined VMS frequency and blood pressure (BP) among 2839 participants of the
Study of Women’s Health Across the Nation (SWAN), a multiethnic, prospective, study of women enrolled
from seven U.S. sites between November 1995 and October 1997. Women were age 42–52, with no history of
CVD, and not postmenopausal at baseline. VMS was defined by the number of days a woman reported VMS
over the 2-week period before each annual visit. Frequent VMS was defined as ‡6 days of VMS; less frequent
VMS was defined 1–5 days of symptoms with asymptomatic women the reference group. BP was measured at
each visit in addition to demographic and clinic factors.
Results: At baseline, 298 women reported frequent VMS, 794 less frequent VMS and 1747 no VMS. More
frequent baseline VMS was associated with higher BP. Compared to no VMS, baseline VMS was associated with
HTN (odds ratio [OR] 1.47, 95% confidence interval [CI]; 1.14–1.88 for infrequent VMS, and OR 1.40, (95% CI;
0.97–2.02 for frequent VMS). Risk for incident pre-HTN or HTN during follow-up was increased among women
with frequent VMS (hazard ratio of 1.39, 95% CI; 1.09–1.79) after adjustment for multiple covariates.
Conclusion: Women with VMS may be more likely to develop HTN compared to women without VMS.
Further research related to VMS including frequency of symptoms is warranted.
Introduction
Hot flashes and night sweats, frequently experi-enced by women transitioning through menopause, are
collectively termed vasomotor symptoms (VMS). The prev-
alence of VMS during the menopausal transition ranges from
42% to 79%.1–4 VMS can occur up to 20 or more episodes per
day in some women, and are associated with changes in va-
sodilatation and autonomic function.5 VMS frequency may
influence vascular changes in women as they age and thus
may influence a woman’s blood pressure (BP) as well. Since
hypertension (HTN) is common among women, particularly
in the peri and postmenopausal years, and is a major risk
factor for cardiac events and stroke,6,7 examining VMS in
association to BP may improve current understanding of BP
during the midlife transition.
To provide information on BP in relation to VMS, we ex-
amined the associations between VMS frequency and BP among
participants enrolled in the Study of Women’s Health Across the
Nation (SWAN), a multiethnic prospective cohort study of
women transitioning through menopause. We hypothesized that
frequency of VMS would be positively associated with BP and
increase the risk for developing HTN over time.
Materials and Methods
Study population
SWAN is a community-based longitudinal study designed
to examine women’s health through the menopausal transi-
tion. Study design and procedures, including recruitment and
enrollment have been described in detail elsewhere.8 Be-
tween November 1995 and October 1997, 3302 women were
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enrolled at 7 geographic sites. Sites used various sampling
frameworks and recruitment strategies to enroll women from
the surrounding communities. All sites enrolled non-
Hispanic Caucasians and a specific minority racial/ethnic
group. For the Boston, Chicago, Pittsburgh, and Detroit sites,
African American women were enrolled, while Chinese,
Hispanic, and Japanese women were enrolled at the Oakland,
CA, Newark, NJ, and Los Angeles, CA, sites respectively.
Eligibility requirements included age between 42 and 52
years upon entry, menses within the 3 months before en-
rollment, and the presence of a uterus and at least one ovary.
Methods used in SWAN were approved by the Institutional
Review Board at each study site. Each participant read and
signed an informed consent document.
Of the 3302 SWAN participants, women who reported a
baseline history of cardiovascular disease (CVD) (stroke,
angina, or heart attack; n= 92), and women missing infor-
mation on baseline VMS frequency (n= 21), BP (n = 10), or
covariates (n = 340) were excluded. The remaining 2839
women were included in cross-sectional analysis of baseline
data. For analysis of within-woman change in BP since
baseline, additional women were excluded if they were on
antihypertensive medications at baseline and/or follow-up
visit 1 (n = 365), had a hysterectomy or bilateral oophorec-
tomy (BSO) at follow-up visit 1 (n = 21), and had incident
CVD at follow-up visit 1 (n = 9). An additional 107 women
who did not have follow-up visits with complete data and/or
missing information on exogenous hormone use (HT) were
excluded. The remaining 2367 women provided 1 or more
observations through follow-up visit 10. For analysis of in-
cident pre-HTN/HTN, of the 2839 women in baseline anal-
ysis, women were excluded if they were not normotensive at
baseline (n = 1385), had a hysterectomy or BSO at follow-up
visit 1 (n = 7), had incident CVD at follow-up visit 1 (n = 5),
or had incomplete data and/or missing information on ex-
ogenous hormone use (HT) use (n = 89). The remaining 1353
women were included in analysis of incident pre-HTN/HTN
through follow-up visit10. For both longitudinal analysis, a
woman’s data were censored at hysterectomy or BSO or at a
reported CVD event, and visits with HT were omitted. For
analysis of change in BP, data also were censored at first use of
antihypertensive medication, which results in a shorter follow-
up time for this analysis (mean follow-up time was 4.3 years).
Measures
Vasomotor symptoms. Information on VMS (i.e., hot
flashes and night sweats) was collected by self-report via the
SWAN questionnaires during each annual study visit. Parti-
cipants were asked how many days over the 2-week period
immediately before the annual visit they experienced any
VMS (not at all, 1–5 days, 6–8 days, 9–13 days, every day).
For the present analysis, VMS frequency was categorized
into three groups (frequent VMS: six or more days with
symptoms; infrequent VMS:1–5 days with symptoms; no
VMS; prior 2 weeks without symptoms), consistent with
prior SWAN analyses.9
Blood pressure. BP was measured according to a stan-
dardized protocol, with readings taken on the right arm, with
the respondent seated and feet flat on the floor for at least 5
minutes before measurement. Respondents were asked to
refrain from smoking or consuming any caffeinated beverage
within 30 minutes of BP measurement. Appropriate cuff size
was determined based on arm circumference. A standard
mercury sphygmomanometer was used to record systolic and
diastolic pressures at the first and fifth phase Korotkoff
sounds. Two sequential BP values were completed, with a
minimum 2-minute rest period between measurements. The
average of the two measures was used in this analysis.
In addition to examining BP levels as a continuous vari-
able, categorical variables were created based on the Seventh
Report of the Joint National Committee on the Prevention,
Detection, Evaluation, and Treatment of High BP ( JNC
VII).10 HTN was defined as SBP ‡140 mmHg, or DBP
‡90 mmHg, or current use of antihypertensive medications
(queried at each annual visit). Pre-HTN was defined as SBP
120–139 mmHg or DBP 80–89 mmHg without medication
use, and normotension was defined as SBP <120 mmHg and
DBP <80 mmHg without medication use.
Covariates. Premenopausal status was defined as a men-
strual period within the past 3 months with no change in cycle
regularity. Early perimenopause was defined as a menses
within the past 3 months with a change in cycle regularity. Late
perimenopause was defined as no menses for three or more
months, but at least one period within the last 12 months.
Postmenopause was defined as no menses for 12 or more
consecutive months with no other reason for the amenorrhea.
Surgical menopause (occurring during follow-up) was defined
as having had a hysterectomy or BSO. By design, all women
were pre- or early perimenopausal at baseline.
Demographic information was collected at baseline in-
cluding race/ethnicity, education level, and parity (any live
births). Information on a number of known risk factors for
HTN was collected at baseline and during follow-up, in-
cluding age, body mass index (BMI, kg/m2), smoking status
(current versus former and never), alcohol consumption
(abstainer, <2 servings/week, 2–7 servings/week, and >7
servings/week), and11anxiety, computed as the sum of fre-
quency of four symptoms (irritability or grouchiness, feeling
tense or nervous, pounding or racing heart, fearful for no
reason) in the past 2 weeks, with scores for each item ranging
from 0 (no days) to 4 (every day); the sum was dichotomized
at the *75th percentile, 4+ vs. <4.12 Level of physical ac-
tivity was assessed at baseline and follow-ups 3, 5, and 9
using the Kaiser Physical Activity Survey adapted from the
Baecke questionnaire.13,14 Because both alcohol consump-
tion and physical activity were stable over time within wo-
man (intra-class correlation = 0.75 and 0.64, respectively),
analysis used baseline rather than time-varying values.
Statistical analysis
Characteristics of the analytic sample at baseline were
compared by baseline VMS frequency groups using chi-
square testing for categorical variables and analysis of co-
variance for continuous variables. The covariate- adjusted
association of baseline VMS frequency with categorized
HTN (normotensive, prehypertensive, and hypertensive) at
baseline was estimated using multinomial logistic regression.
Linear mixed models,15,16 were used to examine the as-
sociations of VMS frequency reported at each visit with the
changes in systolic and diastolic BP (change from baseline to

















































BP measures at the concurrent visit as the VMS reported),
adjusting for baseline age, time since baseline, study site,
race, education level, current menopausal status, baseline
parity, baseline alcohol consumption, baseline physical ac-
tivity, smoking status, current anxiety score, current BMI,
and baseline VMS. Associations of time-varying VMS with
incident pre-HTN or HTN among normotensive participants
at baseline, before and after adjustment for covariates, were
estimated using logistic regression with a complementary
log-log link for discrete survival analysis, to account for the
interval censoring due to assessment of HTN only at annual
visits.17 In sensitivity analysis, we interpolated missing val-
ues of the time-varying covariates for gaps of 1–2 visits based
on covariate values at prior and subsequent visits, analogous
to prior SWAN analysis;18 results were similar to those
presented (data not shown).
Results
At baseline 298 (10.5%) women reported frequent VMS
(six or more days in the prior 2 weeks), 794 (28.0%) women
reported infrequent VMS (between 1 and 5 days of symp-
toms), and 1747 (61.5%) reported no VMS. (Table 1) Mean
and median years of follow-up were 8.2 and 10.0, respec-
tively. Compared with women providing follow-up data,
women with no follow-up visits had slightly higher baseline
mean systolic (119.2 mmHg vs. 115.3 mmHg) and diastolic
BP (76.3 mmHg vs. 74.3 mmHg) and were somewhat more
likely to have pre-HTN or HTN at baseline (58.4% vs. 48.2%).
Women reporting frequent VMS at baseline were on aver-
age older, more likely to be African American, and less edu-
cated compared with those with fewer symptoms. As expected,
women who reported frequent VMS at baseline were more
likely to be early perimenopausal than premenopausal. Wo-
men who reported frequent VMS at baseline were also heavier,
less physically active, more anxious, and more likely to be
current smokers compared to asymptomatic women. Among
women not on antihypertensive medications, mean SBP and
DBP were higher among the more symptomatic women in age-
adjusted models. Women with VMS were also more likely to
be prehypertensive or hypertensive at baseline, as defined by
JNC VII criteria compared to asymptomatic women.
Women who reported frequent VMS at baseline were more
than twice as likely to have HTN at baseline, compared to
asymptomatic women. (Table 2) Frequent VMS was also
significantly associated with pre-HTN. These associations
remained significant when adjusting for age. Further adjust-
ment for multiple demographic factors and CVD risk factors
attenuated these associations. In multivariable models VMS
frequency was no longer associated with either pre-HTN or
HTN. However, having VMS 1–5 days, remained associated
with HTN, which likely reflects the larger sample of women
reporting VMS in the past 1–5 days, compared to the smaller
sample of women reporting frequent VMS.
Table 1. Baseline Characteristics by Baseline Frequency of Vasomotor Symptoms, (n= 2839)
Characteristics
Number of days reported hot flashes/night sweats in the past 2 weeks
0 days n = 1747 1–5 days n= 794 6 or more n = 298 p
Age in years, mean (SE) 46.2 (0.1) 46.5 (0.1) 47.2 (0.2) <0.0001
Race/ethnicity, n (%) <0.0001
African American 393 (22.5) 222 (28.0) 105 (35.2)
Caucasian 907 (51.9) 373 (47.0) 136 (45.6)
Chinese 159 (9.1) 50 (6.3) 13 (4.4)
Hispanic 121 (6.9) 84 (10.6) 29 (9.7)
Japanese 167 (9.6) 65 (8.2) 15 (5.0)
Menopausal status, n (%) <0.0001
Premenopausal 1058 (60.6) 362 (45.6) 113 (37.9)
Early peri-menopausal 689 (39.4) 432 (54.4) 185 (62.1)
Any live births, n (%) 1413 (80.9) 685 (86.3) 253 (84.9) 0.0023
College degree, n (%) 872 (49.9) 303 (38.2) 100 (33.6) <0.0001
Alcohol consumption, n (%) 0.2670
Abstainer 857 (49.1) 377 (47.5) 163 (54.7)
Infrequent (<2 servings/week) 176 (10.1) 88 (11.1) 30 (10.1)
Light to moderate (2–7 servings/week) 473 (27.1) 205 (25.8) 63 (21.1)
Heavy (>7/week) 241 (13.8) 124 (15.6) 42 (14.1)
High anxiety (score ‡4), n (%) 247 (14.1) 226 (28.5) 155 (52.0) <0.0001
BMI, kg/m2 (SE) 27.6 (0.2) 28.6 (0.3) 30.4 (0.4) <0.0001
Current cigarette smoking, n (%) 245 (14.0) 144 (18.1) 68 (22.8) <0.0001
Physical activity, mean (SE)a 7.8 (0.04) 7.7 (0.1) 7.4 (0.1) 0.0398
Systolic BP, mmHg, mean (SE)b 114.2 (0.4) 117.3 (0.6) 118.5 (1.0) <0.0001
Diastolic BP, mm Hg, mean (SE)b 73.9 (0.2) 75.4 (0.4) 75.5 (0.6) 0.0023
Blood pressure categories, n (%) <0.0001
Normotensive 974 (55.8) 364 (45.8) 116 (38.9)
Prehypertensive 477 (27.3) 237 (29.9) 96 (32.2)
Hypertensive 296 (16.9) 193 (24.3) 86 (28.9)
aKaiser physical activity survey total score ranges from 3 to 15, with 15 being highest level of activity.
bExcluding subjects on antihypertensive medications at baseline.
BMI, body mass index; BP, blood pressure; SE, standard error.

















































We next examined the relation between VMS frequency
and change in BP over time (Table 3). Baseline VMS was not
associated with change in SBP or DBP (data not shown).
After adjusting for baseline VMS, and other factors, women
who reported frequent VMS during follow-up had greater
increases in DBP during follow-up. VMS was not related to
changes in SBP.
We also examined the incidence of pre-HTN or HTN by
VMS frequency (Table 4). Compared with absence of VMS,
incidence of pre-HTN or HTN was more likely with occur-
rence of both 1–5 days of VMS and frequent VMS (six or
more days of VMS). After adjustment for covariates, frequent
VMS remained associated with a higher risk for pre-HTN or
HTN compared to asymptomatic women.
Discussion
In this large multi-ethnic cohort of midlife women, more
frequent VMS at baseline were associated with higher BP and
HTN at baseline. During follow-up incident pre-HTN and
HTN was associated with frequent VMS. However, change in
BP over time did not appear to be associated with VMS
frequency during follow-up.
Our study represents one of the largest prospective cohorts
in which VMS and BP has been examined. Other smaller
studies have shown a similar relationship between VMS and
BP. In a study of 20 women, in which BP was measured via
ambulatory BP monitoring, higher SBP levels were observed
among women who reported having VMS compared to wo-
men with no symptoms.19 However, frequency of VMS was
not collected. A similar positive association was observed in
data from the Neighborhood Health Study20 in which 154
midlife women wore an ambulatory BP monitor for 24 hours.
Women who reported VMS had significantly higher SBP
(both daytime and nocturnal) compared to women who
Table 2. Estimated Odds Ratios from Multinomial
Logistic Regression for Baseline Prehypertension












None Reference Reference <0.0001
1–5 days 1.32 (1.09, 1.62) 1.75 (1.40, 2.17)
6+ days 1.69 (1.26, 2.26) 2.44 (1.79, 3.32)
Model 1
None Reference Reference <0.0001
1–5 days 1.31 (1.08, 1.60) 1.69 (1.36, 2.11)
6+ days 1.60 (1.19, 2.14) 2.15 (1.57, 2.94)
Model 2
None Reference Reference <0.0341
1–5 days 1.17 (0.94, 1.46) 1.47 (1.14, 1.88)
6+ days 1.27 (0.91, 1.76) 1.40 (0.97, 2.02)
Model 1=baseline age-adjusted; Model 2= adjusted for baseline
age, study site, race/ethnicity, education, baseline menopausal status,
parity, baseline alcohol consumption, baseline physical activity,
baseline smoking status, baseline anxiety score, and baseline BMI.
VMS, vasomotor symptoms.
Table 3. Estimated Change in Mean BP by VMS
Categories from Mixed Effect Models (n = 2369)
Frequency








None 1.54 (0.27) 1.61 (0.27) 2.10 (0.42)
1–5 days 1.49 (0.26) 1.54 (0.26) 2.01 (0.42)
6+ days 1.97 (0.28) 2.00 (0.28) 2.44 (0.42)
Trend p value 0.16 0.22 0.31
Frequency








None -0.20 (0.20) -0.13 (0.20) 0.09 (0.31)
1–5 days 0.06 (0.19) 0.10 (0.19) 0.29 (0.31)
6+ days 0.34 (0.21) 0.35 (0.20) 0.46 (0.31)
Trend p value 0.003 0.009 0.046
VMS was assessed concurrently with each visit and VMS was
treated as a time-varying covariate. Change in BP at concurrent
visit–baseline BP. Observations were censored at first use of HTN
medications, excluding missing changes in BP, VMS, and
covariates (n = 2369 women with 13,947 observations over a mean
follow-up time of 4.3 years); Estimated changes in mean BP were
calculated at means of all included covariates in each model;
Unadjusted model includes time since baseline, adjusting for
baseline VMS; Model 1: adjusted for age at baseline, time since
baseline, study site, and baseline VMS; Model 2: adjusted for
covariates in model 1 and race, education level, current menopausal
status, baseline parity, baseline alcohol consumption, baseline
physical activity, current smoking status, current anxiety score,
current BMI.
Table 4. Estimated HR for Incident
Prehypertension/Hypertension by VMS Categories,
1353 Women Normotensive at Baseline
Unadjusted HR (95% CI) p
No. observations/
No. events
None Reference 0.0001 6385/620
1–5 days 1.22 (1.01, 1.48)
6+ days 1.62 (1.30, 2.03)
Model 1
None Reference 0.0024 6385/620
1–5 days 1.20 (0.98, 1.46)
6+ days 1.50 (1.19, 1.89)
Model 2
None Reference 0.0443 6257/589
1–5 days 1.08 (0.87, 1.33)
6+ days 1.39 (1.08, 1.79)
VMS was assessed concurrently with each visit and VMS was
treated as a time-varying covariate. Unadjusted: model includes only
current VMS frequency and time since baseline; Model 1: adjusted for
baseline age and site; Model 2: variables including in Model 1, race,
education level, current menopausal status, baseline parity, baseline
alcohol consumption, baseline physical activity, current smoking
status, current anxiety score, current BMI; Prehypertension (SBP 120–
139 mmHg or DBP 80–89 mmHg); hypertension (use of an antihy-
pertensive agent or SBP‡140 mmHg or DBP‡90 mmHg) per JNC VII.
HR, hazard ratio.

















































reported no symptoms, after controlling for age, race/eth-
nicity, BMI, and menopausal status. In contrast, a more re-
cent study of 202 women, aged 45–55 observed no significant
difference in mean SBP between women who reported hot
flashes compared to those who were asymptomatic.21 How-
ever, the investigators did observe a significant and transient
increase in SBP during the 10 minutes before individual hot
flashes episodes. In a cross-sectional analysis of 5523 wo-
men, Gast et al. showed evidence for a positive association
between reported VMS and BP. These associations were in
part, but not fully accounted for, by confounders such as
BMI.22
Prior studies suggest an association between VMS and
cardiovascular risk parameters that may also influence BP.
Thurston and colleagues, using data from SWAN Heart,
observed that women who reported having any hot flashes
over a 2-week period were more likely to have reduced flow-
mediated dilation, a marker of subclinical CVD.23 Using the
same study population, these symptomatic women were 63%
more likely to have aortic calcification compared with wo-
men who reported no symptoms.23 Other subclinical markers
of CVD such as carotid intimal thickness also appear to be
associated with hot flash symptoms in women.9 Although
findings are mixed, additional studies suggest higher rates of
coronary heart disease among women who report VMS
compared with those who do not.24,25
VMS is highly prevalent among women transitioning through
menopause; with many women reporting increased frequency
during late peri-menopause and early postmenopause.1–4 The
exact physiologic mechanisms behind VMS are not clearly
understood. However, data suggest that changes in core body
temperature and vascular function occur transiently around the
time of a VMS episode.5 As peripheral temperature increases,
skin vasodilation occurs, resulting in an increase in skin blood
flow and dispersion of heat.5 Additional studies have observed
that the main metabolite of norepinephrine, 3-methoxy-4-
hydroxyphenylglycol (MHPG), is increased in women with
VMS,26,27 while women without VMS demonstrate no such
increase in MHPG. Current knowledge regarding the physi-
ology of VMS in the menopausal transition suggests the role of
autonomic regulation may be important.28–31 Given these rela-
tionships, along with observational studies, VMS may be asso-
ciated with incident HTN; however, we did not observe a strong
relationship between VMS frequency over time and increases in
BP. Over time, small increases in BP may contribute to the
development of preHTN and HTN. However, the differences
may also reflect the examination of continuous BP measures
versus BP categories. Understanding the relationship between
VMS and BP including duration of VMS warrants further study.
Several strengths and limitations exist in this study. At
each annual visit, women were asked about the number of
days in the prior 2 weeks in which they experienced hot
flashes and/or night sweats, without specification of how
many VMS events they were having on those days. Although
this method of asking about VMS is widely used, it would
lead to reduced precision in regard to VMS frequency and a
bias toward the null hypothesis that BP does not differ by
VMS frequency. Thus, differentiating between women with
20 VMS per day and those with three per day is not possible;
however, SWAN’s longitudinal design and multi-ethnic co-
hort does allow an examination of days of symptoms over
several years.
Conclusion
Among a multi-ethnic cohort of midlife women, those
who experienced frequent VMS had an increased risk for
incident pre-HTN and HTN, although a change BP level
over time was not associated with VMS. Further research is
needed to understand the relationship between VMS and BP
as women age.
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